Medi USA announced the launch of restiffic compressive foot wrap, a new drug-free option for patients with restless legs syndrome (RLS). It is cleared by the Food and Drug Administration (FDA) as a Class 1 device.
Restiffic works by promoting gentle, relaxing pressure on the abductor hallucis and flexor hallucis brevis muscles in the foot. It helps decrease uncontrollable impulses to move the legs and creates a soothing effect for improved sleep. The foot wrap comes with adjustable compression and a Flexor-T pad that supports the ball of the foot for a more intuitive fit.
Restiffic should not be used in patients with neuropathy, poor circulation, peripheral vascular disease, varicose veins, deep vein thrombosis, history of blood clots, or foot and/or leg swelling.
In a 2013 single-arm, open-label clinical trial, the use of restiffic was evaluated in 30 otherwise healthy adults diagnosed with moderate to severe primary RLS. Efficacy was measured using the International RLS Study Group (IRLSS) Rating Scale and the physician-generated Clinical Global Impression (CGI) scale. Data showed that using restiffic resulted in 97% of patients experiencing a significant reduction in RLS symptoms and a 69% reduction in the severity of symptoms after 6 weeks of use. Also, restiffic proved to be 40% more effective than the leading pharmacologic treatment for RLS. Physicians reported no adverse effects in 93% of patients.
Restiffic is available for purchase online with a prescription.
For more information call (855) 700-6875 or visit Restiffic.com.